ssRNA Viruses negative-sense

CCHEMISTRY METALLURGY C12Biochemistry C12NMICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA

C12N2760/00ssRNA Viruses negative-sense

C12N2760/00011ssRNA Viruses negative-sense C12N2760/00021Viruses as such C12N2760/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/00023Virus like particles [VLP] C12N2760/00031Uses of virus other than therapeutic or vaccine C12N2760/00032Use of virus as therapeutic agent, other than vaccine C12N2760/00033Use of viral protein as therapeutic agent other than vaccine C12N2760/00034Use of virus or viral component as vaccine C12N2760/00041Use of virus, viral particle or viral elements as a vector C12N2760/00042virus or viral particle as vehicle C12N2760/00043viral genome or elements thereof as genetic vector C12N2760/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/00045Special targeting system for viral vectors C12N2760/00051Methods of production or purification of viral material C12N2760/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/00061Methods of inactivation or attenuation C12N2760/00062by genetic engineering C12N2760/00063by chemical treatment C12N2760/00064by serial passage C12N2760/00071Demonstrated in vivo effect C12N2760/00088For redistribution C12N2760/10011Arenaviridae C12N2760/10021Viruses as such C12N2760/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/10023Virus like particles [VLP] C12N2760/10031Uses of virus other than therapeutic or vaccine C12N2760/10032Use of virus as therapeutic agent, other than vaccine C12N2760/10033Use of viral protein as therapeutic agent other than vaccine C12N2760/10034Use of virus or viral component as vaccine C12N2760/10041Use of virus, viral particle or viral elements as a vector C12N2760/10042virus or viral particle as vehicle C12N2760/10043viral genome or elements thereof as genetic vector C12N2760/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/10045Special targeting system for viral vectors C12N2760/10051Methods of production or purification of viral material C12N2760/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/10061Methods of inactivation or attenuation C12N2760/10062by genetic engineering C12N2760/10063by chemical treatment C12N2760/10064by serial passage C12N2760/10071Demonstrated in vivo effect C12N2760/10088For redistribution C12N2760/10111Deltavirus C12N2760/10121Viruses as such C12N2760/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/10123Virus like particles [VLP] C12N2760/10131Uses of virus other than therapeutic or vaccine C12N2760/10132Use of virus as therapeutic agent, other than vaccine C12N2760/10133Use of viral protein as therapeutic agent other than vaccine C12N2760/10134Use of virus or viral component as vaccine C12N2760/10141Use of virus, viral particle or viral elements as a vector C12N2760/10142virus or viral particle as vehicle C12N2760/10143viral genome or elements thereof as genetic vector C12N2760/10144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/10145Special targeting system for viral vectors C12N2760/10151Methods of production or purification of viral material C12N2760/10152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/10161Methods of inactivation or attenuation C12N2760/10162by genetic engineering C12N2760/10163by chemical treatment C12N2760/10164by serial passage C12N2760/10171Demonstrated in vivo effect C12N2760/10188For redistribution C12N2760/12011Bunyaviridae C12N2760/12021Viruses as such C12N2760/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/12023Virus like particles [VLP] C12N2760/12031Uses of virus other than therapeutic or vaccine C12N2760/12032Use of virus as therapeutic agent, other than vaccine C12N2760/12033Use of viral protein as therapeutic agent other than vaccine C12N2760/12034Use of virus or viral component as vaccine C12N2760/12041Use of virus, viral particle or viral elements as a vector C12N2760/12042virus or viral particle as vehicle C12N2760/12043viral genome or elements thereof as genetic vector C12N2760/12044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/12045Special targeting system for viral vectors C12N2760/12051Methods of production or purification of viral material C12N2760/12052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/12061Methods of inactivation or attenuation C12N2760/12062by genetic engineering C12N2760/12063by chemical treatment C12N2760/12064by serial passage C12N2760/12071Demonstrated in vivo effect C12N2760/12088For redistribution C12N2760/12111Hantavirus C12N2760/12121Viruses as such C12N2760/12122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/12123Virus like particles [VLP] C12N2760/12131Uses of virus other than therapeutic or vaccine C12N2760/12132Use of virus as therapeutic agent, other than vaccine C12N2760/12133Use of viral protein as therapeutic agent other than vaccine C12N2760/12134Use of virus or viral component as vaccine C12N2760/12141Use of virus, viral particle or viral elements as a vector C12N2760/12142virus or viral particle as vehicle C12N2760/12143viral genome or elements thereof as genetic vector C12N2760/12144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/12145Special targeting system for viral vectors C12N2760/12151Methods of production or purification of viral material C12N2760/12152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/12161Methods of inactivation or attenuation C12N2760/12162by genetic engineering C12N2760/12163by chemical treatment C12N2760/12164by serial passage C12N2760/12171Demonstrated in vivo effect C12N2760/12188For redistribution C12N2760/12211Phlebovirus C12N2760/12221Viruses as such C12N2760/12222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/12223Virus like particles [VLP] C12N2760/12231Uses of virus other than therapeutic or vaccine C12N2760/12232Use of virus as therapeutic agent, other than vaccine C12N2760/12233Use of viral protein as therapeutic agent other than vaccine C12N2760/12234Use of virus or viral component as vaccine C12N2760/12241Use of virus, viral particle or viral elements as a vector C12N2760/12242virus or viral particle as vehicle C12N2760/12243viral genome or elements thereof as genetic vector C12N2760/12244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/12245Special targeting system for viral vectors C12N2760/12251Methods of production or purification of viral material C12N2760/12252relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/12261Methods of inactivation or attenuation C12N2760/12262by genetic engineering C12N2760/12263by chemical treatment C12N2760/12264by serial passage C12N2760/12271Demonstrated in vivo effect C12N2760/12288For redistribution C12N2760/14011Filoviridae C12N2760/14021Viruses as such C12N2760/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/14023Virus like particles [VLP] C12N2760/14031Uses of virus other than therapeutic or vaccine C12N2760/14032Use of virus as therapeutic agent, other than vaccine C12N2760/14033Use of viral protein as therapeutic agent other than vaccine C12N2760/14034Use of virus or viral component as vaccine C12N2760/14041Use of virus, viral particle or viral elements as a vector C12N2760/14042virus or viral particle as vehicle C12N2760/14043viral genome or elements thereof as genetic vector C12N2760/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/14045Special targeting system for viral vectors C12N2760/14051Methods of production or purification of viral material C12N2760/14052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/14061Methods of inactivation or attenuation C12N2760/14062by genetic engineering C12N2760/14063by chemical treatment C12N2760/14064by serial passage C12N2760/14071Demonstrated in vivo effect C12N2760/14088For redistribution C12N2760/14111Ebolavirus C12N2760/14121Viruses as such C12N2760/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/14123Virus like particles [VLP] C12N2760/14131Uses of virus other than therapeutic or vaccine C12N2760/14132Use of virus as therapeutic agent, other than vaccine C12N2760/14133Use of viral protein as therapeutic agent other than vaccine C12N2760/14134Use of virus or viral component as vaccine C12N2760/14141Use of virus, viral particle or viral elements as a vector C12N2760/14142virus or viral particle as vehicle C12N2760/14143viral genome or elements thereof as genetic vector C12N2760/14144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/14145Special targeting system for viral vectors C12N2760/14151Methods of production or purification of viral material C12N2760/14152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/14161Methods of inactivation or attenuation C12N2760/14162by genetic engineering C12N2760/14163by chemical treatment C12N2760/14164by serial passage C12N2760/14171Demonstrated in vivo effect C12N2760/14188For redistribution C12N2760/14211Marburgvirus C12N2760/14221Viruses as such C12N2760/14222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/14223Uses of virus other than therapeutic or vaccine C12N2760/14231Uses of virus other than therapeutic or vaccine C12N2760/14232Use of virus as therapeutic agent, other than vaccine C12N2760/14233Use of viral protein as therapeutic agent other than vaccine C12N2760/14234Use of virus or viral component as vaccine C12N2760/14241Use of virus, viral particle or viral elements as a vector C12N2760/14242virus or viral particle as vehicle C12N2760/14243viral genome or elements thereof as genetic vector C12N2760/14244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/14245Special targeting system for viral vectors C12N2760/14251Methods of production or purification of viral material C12N2760/14252relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/14261Methods of inactivation or attenuation C12N2760/14262by genetic engineering C12N2760/14263by chemical treatment C12N2760/14264by serial passage C12N2760/14271Demonstrated in vivo effect C12N2760/14288For redistribution C12N2760/16011Orthomyxoviridae C12N2760/16021Viruses as such C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/16023Virus like particles [VLP] C12N2760/16031Uses of virus other than therapeutic or vaccine C12N2760/16032Use of virus as therapeutic agent, other than vaccine C12N2760/16033Use of viral protein as therapeutic agent other than vaccine C12N2760/16034Use of virus or viral component as vaccine C12N2760/16041Use of virus, viral particle or viral elements as a vector C12N2760/16042virus or viral particle as vehicle C12N2760/16043viral genome or elements thereof as genetic vector C12N2760/16044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/16045Special targeting system for viral vectors C12N2760/16051Methods of production or purification of viral material C12N2760/16052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/16061Methods of inactivation or attenuation C12N2760/16062by genetic engineering C12N2760/16063by chemical treatment C12N2760/16064by serial passage C12N2760/16071Demonstrated in vivo effect C12N2760/16088For redistribution C12N2760/16111Influenzavirus A C12N2760/16121Viruses as such C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/16123Virus like particles [VLP] C12N2760/16131Uses of virus other than therapeutic or vaccine C12N2760/16132Use of virus as therapeutic agent, other than vaccine C12N2760/16133Use of viral protein as therapeutic agent other than vaccine C12N2760/16134Use of virus or viral component as vaccine C12N2760/16141Use of virus, viral particle or viral elements as a vector C12N2760/16142virus or viral particle as vehicle C12N2760/16143viral genome or elements thereof as genetic vector C12N2760/16144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/16145Special targeting system for viral vectors C12N2760/16151Methods of production or purification of viral material C12N2760/16152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/16161Methods of inactivation or attenuation C12N2760/16162by genetic engineering C12N2760/16163by chemical treatment C12N2760/16164by serial passage C12N2760/16171Demonstrated in vivo effect C12N2760/16188For redistribution C12N2760/16211Influenzavirus B C12N2760/16221Viruses as such C12N2760/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/16223Virus like particles [VLP] C12N2760/16231Uses of virus other than therapeutic or vaccine C12N2760/16232Use of virus as therapeutic agent, other than vaccine C12N2760/16233Use of viral protein as therapeutic agent other than vaccine C12N2760/16234Use of virus or viral component as vaccine C12N2760/16241Use of virus, viral particle or viral elements as a vector C12N2760/16242virus or viral particle as vehicle C12N2760/16243viral genome or elements thereof as genetic vector C12N2760/16244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/16245Special targeting system for viral vectors C12N2760/16251Methods of production or purification of viral material C12N2760/16252relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/16261Methods of inactivation or attenuation C12N2760/16262by genetic engineering C12N2760/16263by chemical treatment C12N2760/16264by serial passage C12N2760/16271Demonstrated in vivo effect C12N2760/16288For redistribution C12N2760/16311Influenzavirus C C12N2760/16321Viruses as such C12N2760/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/16323Virus like particles [VLP] C12N2760/16331Uses of virus other than therapeutic or vaccine C12N2760/16332Use of virus as therapeutic agent, other than vaccine C12N2760/16333Use of viral protein as therapeutic agent other than vaccine C12N2760/16334Use of virus or viral component as vaccine C12N2760/16341Use of virus, viral particle or viral elements as a vector C12N2760/16342virus or viral particle as vehicle C12N2760/16343viral genome or elements thereof as genetic vector C12N2760/16344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/16345Special targeting system for viral vectors C12N2760/16351Methods of production or purification of viral material C12N2760/16352relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/16361Methods of inactivation or attenuation C12N2760/16362by genetic engineering C12N2760/16363by chemical treatment C12N2760/16364by serial passage C12N2760/16371Demonstrated in vivo effect C12N2760/16388For redistribution C12N2760/18011Paramyxoviridae C12N2760/18021Viruses as such C12N2760/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18023Virus like particles [VLP] C12N2760/18031Uses of virus other than therapeutic or vaccine C12N2760/18032Use of virus as therapeutic agent, other than vaccine C12N2760/18033Use of viral protein as therapeutic agent other than vaccine C12N2760/18034Use of virus or viral component as vaccine C12N2760/18041Use of virus, viral particle or viral elements as a vector C12N2760/18042virus or viral particle as vehicle C12N2760/18043viral genome or elements thereof as genetic vector C12N2760/18044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18045Special targeting system for viral vectors C12N2760/18051Methods of production or purification of viral material C12N2760/18052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18061Methods of inactivation or attenuation C12N2760/18062by genetic engineering C12N2760/18063by chemical treatment C12N2760/18064by serial passage C12N2760/18071Demonstrated in vivo effect C12N2760/18088For redistribution C12N2760/18111Avulavirus C12N2760/18121Viruses as such C12N2760/18122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18123Virus like particles [VLP] C12N2760/18131Uses of virus other than therapeutic or vaccine C12N2760/18132Use of virus as therapeutic agent, other than vaccine C12N2760/18133Use of viral protein as therapeutic agent other than vaccine C12N2760/18134Use of virus or viral component as vaccine C12N2760/18141Use of virus, viral particle or viral elements as a vector C12N2760/18142virus or viral particle as vehicle C12N2760/18143viral genome or elements thereof as genetic vector C12N2760/18144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18145Special targeting system for viral vectors C12N2760/18151Methods of production or purification of viral material C12N2760/18152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18161Methods of inactivation or attenuation C12N2760/18162by genetic engineering C12N2760/18163by chemical treatment C12N2760/18164by serial passage C12N2760/18171Demonstrated in vivo effect C12N2760/18188For redistribution C12N2760/18211Henipavirus C12N2760/18221Viruses as such C12N2760/18222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18223Virus like particles [VLP] C12N2760/18231Uses of virus other than therapeutic or vaccine C12N2760/18232Use of virus as therapeutic agent, other than vaccine C12N2760/18233Use of viral protein as therapeutic agent other than vaccine C12N2760/18234Use of virus or viral component as vaccine C12N2760/18241Use of virus, viral particle or viral elements as a vector C12N2760/18242virus or viral particle as vehicle C12N2760/18243viral genome or elements thereof as genetic vector C12N2760/18244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18245Special targeting system for viral vectors C12N2760/18251Methods of production or purification of viral material C12N2760/18252relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18261Methods of inactivation or attenuation C12N2760/18262by genetic engineering C12N2760/18263by chemical treatment C12N2760/18264by serial passage C12N2760/18271Demonstrated in vivo effect C12N2760/18288For redistribution C12N2760/18311Metapneumovirus C12N2760/18321Viruses as such C12N2760/18322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18323Virus like particles [VLP] C12N2760/18331Uses of virus other than therapeutic or vaccine C12N2760/18332Use of virus as therapeutic agent, other than vaccine C12N2760/18333Use of viral protein as therapeutic agent other than vaccine C12N2760/18334Use of virus or viral component as vaccine C12N2760/18341Use of virus, viral particle or viral elements as a vector C12N2760/18342virus or viral particle as vehicle C12N2760/18343viral genome or elements thereof as genetic vector C12N2760/18344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18345Special targeting system for viral vectors C12N2760/18351Methods of production or purification of viral material C12N2760/18352relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18361Methods of inactivation or attenuation C12N2760/18362by genetic engineering C12N2760/18363by chemical treatment C12N2760/18364by serial passage C12N2760/18371Demonstrated in vivo effect C12N2760/18388For redistribution C12N2760/18411Morbillivirus C12N2760/18421Viruses as such C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18423Virus like particles [VLP] C12N2760/18431Uses of virus other than therapeutic or vaccine C12N2760/18432Use of virus as therapeutic agent, other than vaccine C12N2760/18433Use of viral protein as therapeutic agent other than vaccine C12N2760/18434Use of virus or viral component as vaccine C12N2760/18441Use of virus, viral particle or viral elements as a vector C12N2760/18442virus or viral particle as vehicle C12N2760/18443viral genome or elements thereof as genetic vector C12N2760/18444Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18445Special targeting system for viral vectors C12N2760/18451Methods of production or purification of viral material C12N2760/18452relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18461Methods of inactivation or attenuation C12N2760/18462by genetic engineering C12N2760/18463by chemical treatment C12N2760/18464by serial passage C12N2760/18471Demonstrated in vivo effect C12N2760/18488For redistribution C12N2760/18511Pneumovirus C12N2760/18521Viruses as such C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18523Virus like particles [VLP] C12N2760/18531Uses of virus other than therapeutic or vaccine C12N2760/18532Use of virus as therapeutic agent, other than vaccine C12N2760/18533Use of viral protein as therapeutic agent other than vaccine C12N2760/18534Use of virus or viral component as vaccine C12N2760/18541Use of virus, viral particle or viral elements as a vector C12N2760/18542virus or viral particle as vehicle C12N2760/18543viral genome or elements thereof as genetic vector C12N2760/18544Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18545Special targeting system for viral vectors C12N2760/18551Methods of production or purification of viral material C12N2760/18552relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18561Methods of inactivation or attenuation C12N2760/18562by genetic engineering C12N2760/18563by chemical treatment C12N2760/18564by serial passage C12N2760/18571Demonstrated in vivo effect C12N2760/18588For redistribution C12N2760/18611Respirovirus C12N2760/18621Viruses as such C12N2760/18622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18623Virus like particles [VLP] C12N2760/18631Uses of virus other than therapeutic or vaccine C12N2760/18632Use of virus as therapeutic agent, other than vaccine C12N2760/18633Use of viral protein as therapeutic agent other than vaccine C12N2760/18634Use of virus or viral component as vaccine C12N2760/18641Use of virus, viral particle or viral elements as a vector C12N2760/18642virus or viral particle as vehicle C12N2760/18643viral genome or elements thereof as genetic vector C12N2760/18644Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18645Special targeting system for viral vectors C12N2760/18651Methods of production or purification of viral material C12N2760/18652relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18661Methods of inactivation or attenuation C12N2760/18662by genetic engineering C12N2760/18663by chemical treatment C12N2760/18664by serial passage C12N2760/18671Demonstrated in vivo effect C12N2760/18688For redistribution C12N2760/18711Rubulavirus C12N2760/18721Viruses as such C12N2760/18722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18723Virus like particles [VLP] C12N2760/18731Uses of virus other than therapeutic or vaccine C12N2760/18732Use of virus as therapeutic agent, other than vaccine C12N2760/18733Use of viral protein as therapeutic agent other than vaccine C12N2760/18734Use of virus or viral component as vaccine C12N2760/18741Use of virus, viral particle or viral elements as a vector C12N2760/18742virus or viral particle as vehicle C12N2760/18743viral genome or elements thereof as genetic vector C12N2760/18744Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/18745Special targeting system for viral vectors C12N2760/18751Methods of production or purification of viral material C12N2760/18752relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18761Methods of inactivation or attenuation C12N2760/18762by genetic engineering C12N2760/18763by chemical treatment C12N2760/18764by serial passage C12N2760/18771Demonstrated in vivo effect C12N2760/18788For redistribution C12N2760/18811Sendai virus C12N2760/18821Viruses as such C12N2760/18822New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/18823Virus like particles [VLP] C12N2760/18831Uses of virus other than therapeutic or vaccine C12N2760/18832Use of virus as therapeutic agent, other than vaccine C12N2760/18833Use of viral protein as therapeutic agent other than vaccine C12N2760/18834Use of virus or viral component as vaccine C12N2760/18841Use of virus, viral particle or viral elements as a vector C12N2760/18842virus or viral particle as vehicle C12N2760/18843viral genome or elements thereof as genetic vector C12N2760/18845Special targeting system for viral vectors C12N2760/18851Methods of production or purification of viral material C12N2760/18852relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/18861Methods of inactivation or attenuation C12N2760/18862by genetic engineering C12N2760/18863by chemical treatment C12N2760/18864by serial passage C12N2760/18871Demonstrated in vivo effect C12N2760/18888For redistribution C12N2760/20011Rhabdoviridae C12N2760/20021Viruses as such C12N2760/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/20023Virus like particles [VLP] C12N2760/20031Uses of virus other than therapeutic or vaccine C12N2760/20032Use of virus as therapeutic agent, other than vaccine C12N2760/20033Use of viral protein as therapeutic agent other than vaccine C12N2760/20034Use of virus or viral component as vaccine C12N2760/20041Use of virus, viral particle or viral elements as a vector C12N2760/20042virus or viral particle as vehicle C12N2760/20043viral genome or elements thereof as genetic vector C12N2760/20044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/20045Special targeting system for viral vectors C12N2760/20051Methods of production or purification of viral material C12N2760/20052relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/20061Methods of inactivation or attenuation C12N2760/20062by genetic engineering C12N2760/20063by chemical treatment C12N2760/20064by serial passage C12N2760/20071Demonstrated in vivo effect C12N2760/20088For redistribution C12N2760/20111Lyssavirus C12N2760/20121Viruses as such C12N2760/20122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/20123Virus like particles [VLP] C12N2760/20131Uses of virus other than therapeutic or vaccine C12N2760/20132Use of virus as therapeutic agent, other than vaccine C12N2760/20133Use of viral protein as therapeutic agent other than vaccine C12N2760/20134Use of virus or viral component as vaccine C12N2760/20141Use of virus, viral particle or viral elements as a vector C12N2760/20142virus or viral particle as vehicle C12N2760/20143viral genome or elements thereof as genetic vector C12N2760/20144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/20145Special targeting system for viral vectors C12N2760/20151Methods of production or purification of viral material C12N2760/20152relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/20161Methods of inactivation or attenuation C12N2760/20162by genetic engineering C12N2760/20163by chemical treatment C12N2760/20164by serial passage C12N2760/20171Demonstrated in vivo effect C12N2760/20188For redistribution C12N2760/20211Vesiculovirus C12N2760/20221Viruses as such C12N2760/20222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2760/20223Virus like particles [VLP] C12N2760/20231Uses of virus other than therapeutic or vaccine C12N2760/20232Use of virus as therapeutic agent, other than vaccine C12N2760/20233Use of viral protein as therapeutic agent other than vaccine C12N2760/20234Use of virus or viral component as vaccine C12N2760/20241Use of virus, viral particle or viral elements as a vector C12N2760/20242virus or viral particle as vehicle C12N2760/20243viral genome or elements thereof as genetic vector C12N2760/20244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2760/20245Special targeting system for viral vectors C12N2760/20251Methods of production or purification of viral material C12N2760/20252relating to complementing cells and packaging systems for producing virus or viral particles C12N2760/20261Methods of inactivation or attenuation C12N2760/20262by genetic engineering C12N2760/20263by chemical treatment C12N2760/20264by serial passage C12N2760/20271Demonstrated in vivo effect C12N2760/20288For redistribution